Cogstate Expands Executive Team with Key Scientific Appointments

October 1, 2020

Chris Edgar named Chief Science Officer and Paul Maruff named Chief Innovation Officer  

Melbourne, VIC, Australia; New Haven, CT, USA, October 1, 2020 — Neuroscience technology company, Cogstate Ltd (ASX.CGS), announced today the appointment of Chris Edgar, PhD as Chief Science Officer and Prof. Paul Maruff, PhD as Chief Innovation Officer. These appointments represent an expansion of the executive leadership team with strengthened scientific capacity as the company continues to meet the growing demand for transformative innovations in clinical trials and healthcare.

As Chief Science Officer, Dr. Edgar will continue to advise Cogstate customers on clinical endpoint strategy and will set the strategic vision for Cogstate’s global scientific services. He will lead a team of clinical experts focused on the optimization, execution and analyses of cognitive and behavioral assessments and related data quality assurance solutions for improved signal detection and excellence in trial design and conduct.

Moving into the newly created role of Chief Innovation Officer, Prof. Maruff will lead efforts to continue to refine existing Cogstate technologies as well as identifying and developing novel methods for assessment of cognition and behaviour. He will continue to oversee Cogstate relationships supporting innovation and development with partners from pharmaceutical and biotechnology companies and with key industry and academic groups central to the scientific advancements of Cogstate technologies.

“Adding scientific strength to the Cogstate leadership team will further position us for this current phase of growth as we continue to see increasing demand for strong, stable delivery supported by rapid, robust innovation,” said Brad O’Connor, Cogstate CEO. “Among the current opportunities for the company are awards in late phase global clinical trial programs, the increased need for remote data collection and smart-phone based assessment, as well as rapidly evolving needs in healthcare for early detection of cognitive impairment. Dr. Edgar’s experience in pharmaceutical and contract research organizations brings an enormous depth to our drug development expertise and measurement science excellence in clinical trials. With his expertise, Paul can re-double his efforts to bring forward new strategies for measuring disease-related and treatment-related changes in cognition, remaining at the center of innovation at Cogstate.”

About Chris Edgar
Dr. Chris Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Dr. Edgar is also a key advisor to Cogstate’s commercial and product teams for the application of new technologies and approaches aligned with industry needs. Prior to joining Cogstate as Senior Vice President, Clinical Science in 2018, Dr. Edgar oversaw clinical endpoint strategy for multiple neuroscience indications in the Patient-Centered Outcomes Research group at Roche. He holds a PhD in psychopharmacology from Northumbria University and has nearly two decades of pharmaceutical industry experience. Dr. Edgar has held other key industry positions including Clinical Scientist at Roche on Schizophrenia and Alzheimer’s disease drug development programs, Senior Clinical Lead for rater training and data quality at Bracket, and Scientific Director at Cognitive Drug Research Ltd., a computerized cognitive assessment company.

About Paul Maruff
Professor Paul Maruff is one of the founders of Cogstate and served as Chief Science Officer before taking on the role of Chief Innovation Officer. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioral and cognitive dysfunction. Prof. Maruff’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to guide decision making in drug development and in clinical medicine. He has worked extensively on methods to identify subtle neurocognitive impairment—and to assess the efficacy of pharmacological treatment—in Alzheimer’s disease, mild cognitive impairment and the HIV dementia complex. He has extended this approach to identify cognitive dysfunction and monitor treatment efficacy in psychiatric diseases such as schizophrenia, obsessive-compulsive disorder and depression in adults, attention deficit disorder, developmental dyspraxia and substance abuse in children. Paul remains an active researcher; he is appointed Professor at the Florey Institute for Neuroscience and Mental Health, and he is currently clinical co-chair of the Australian Imaging Biomarkers and Lifestyle (AIBL) study. Paul has published over 450 research articles in international peer-reviewed scientific journals and has co-authored 15 book chapters.


Back to News